Home » Newsletters » BioWorld Science

BioWorld Science

April 17, 2008

View Archived Issues

Potentially active ST-246 exposure levels achieved in phase I study

CMX-001 protects against herpes virus infection in mice

Celera grants Merck access to cancer targets for RNAi therapeutics

PAION to acquire CeNeS and discontinue development of neuroprotectant enecadin

Antisoma licenses rights to Betagenon's AMPK activators in cancer indications

Vicriviroc begins phase II study in treatment-naive HIV patients

Novel non-nucleoside reverse transcriptase inhibitor synthesized at Merck

Merck reports chemical structure of MK-0731

Basilea initiates additional phase III study of antifungal isavuconazole

Debiopharm enters license agreement with Airmid to develop ShK peptide Debio-0824

Biovitrum and Symphogen initiate clinical study of RhD polyclonal antibody Sym-001

OncoMed to provide SynCo with batches of antibody OMP-21M18 for phase I clinical trials

KV Pharmaceutical launches estradiol transdermal spray Evamist in the U.S.

Mundipharma reports results from study of Flutiform in asthmatic pediatric patients

Paratek's novel tetracycline derivative shows potential for treating spinal muscular atrophy

BHQ-880 effective in preclinical models of tumor-induced bone disease

Novel antiinfectious agents reported in recent Wockhardt and University of South Florida patents

New therapeutic options for gastrointestinal disorders described in recent patent literature

Recent patents disclose novel therapeutic agents for obesity and lipoprotein disorders

Theratechnologies treats last patient in phase III trial of tesamorelin in lipodystrophy

European orphan drug designations for farletuzumab and MORAb-009

Treximet receives FDA approval for acute treatment of migraine

Type 2 diabetes compound KB-3305 successfully completes first phase I study

ArQule decides against further clinical testing of ARQ-171

AEterna completes recruitment for first phase III cetrorelix trial in BPH

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026